Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06074705 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-1471a In Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06074705 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo Co.. The registered enrollment target is 17 participants.
The verdict
NCT06074705, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.
Interventions
- DRUG DS-1471a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-08-04 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06074705
The ClinicalTrials.gov registry entry for NCT06074705 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-1471a is the first listed.
NCT06074705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06074705 about?
NCT06074705 is a clinical study titled "A Study of DS-1471a In Subjects With Advanced Solid Tumors". This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT06074705?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-08-04. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT06074705?
The interventions under investigation include: DS-1471a (DRUG).
Who is sponsoring clinical trial NCT06074705?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.